Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Ulrich Germing

Showing results (321-330 of 339) with videos related to

Pageof 34
Sort By:
The Lancet. Haematology|January 29, 2021
Outcomes of patients with chronic myelomonocytic leukaemia treated with non-curative therapies: a retrospective cohort studyLisa Pleyer, Michael Leisch, Alexandra Kourakli, et al.
Leukemia|August 5, 2024
Transfusion independence after lenalidomide discontinuation in patients with del(5q) myelodysplastic neoplasm: a HARMONY Alliance studyElena Crisà, Elvira Mora, Ulrich Germing, et al.
Blood Cancer Journal|April 8, 2025
Real-world experience with first-line CPX-351 treatment in patients with acute myeloid leukemia - long-term follow-up with focus on younger patientsChristina Rautenberg, Jan Moritz Middeke, Christoph Röllig, et al.
Blood Cancer Journal|October 5, 2021
Real-world experience of CPX-351 as first-line treatment for patients with acute myeloid leukemiaChristina Rautenberg, Friedrich Stölzel, Christoph Röllig, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 17, 2023
Real-World Validation of Molecular International Prognostic Scoring System for Myelodysplastic SyndromesElisabetta Sauta, Marie Robin, Matteo Bersanelli, et al.
Blood Cancer Journal|July 15, 2025
Age-dependent phenotypic and molecular evolution of pediatric MDS arising from GATA2 deficiencyLili Kotmayer, Emilia J Kozyra, Guolian Kang, et al.
The New England Journal of Medicine|January 9, 2020
Luspatercept in Patients with Lower-Risk Myelodysplastic SyndromesPierre Fenaux, Uwe Platzbecker, Ghulam J Mufti, et al.
Leukemia|April 30, 2026
How should myelodysplastic neoplasms with isolated deletion 5q and TP53 multihit alterations be classified?Maria Julia Montoro, Pamela Acha, Claudia Haferlach, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 27, 2026
Molecular-Based Ecosystem to Improve Personalized Medicine in Chronic Myelomonocytic LeukemiaLuca Lanino, Anthony M Hunter, Nico Gagelmann, et al.
Leukemia & Lymphoma|August 25, 2012
Rationale for the clinical application of flow cytometry in patients with myelodysplastic syndromes: position paper of an International Consortium and the European LeukemiaNet Working GroupArjan A van de Loosdrecht, Robin Ireland, Wolfgang Kern, et al.
Pageof 34

Showing results (321-330 of 339) with videos related to

Sort By:
Pageof 34
The Lancet. Haematology|January 29, 2021
Outcomes of patients with chronic myelomonocytic leukaemia treated with non-curative therapies: a retrospective cohort studyLisa Pleyer, Michael Leisch, Alexandra Kourakli, et al.
Leukemia|August 5, 2024
Transfusion independence after lenalidomide discontinuation in patients with del(5q) myelodysplastic neoplasm: a HARMONY Alliance studyElena Crisà, Elvira Mora, Ulrich Germing, et al.
Blood Cancer Journal|April 8, 2025
Real-world experience with first-line CPX-351 treatment in patients with acute myeloid leukemia - long-term follow-up with focus on younger patientsChristina Rautenberg, Jan Moritz Middeke, Christoph Röllig, et al.
Blood Cancer Journal|October 5, 2021
Real-world experience of CPX-351 as first-line treatment for patients with acute myeloid leukemiaChristina Rautenberg, Friedrich Stölzel, Christoph Röllig, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 17, 2023
Real-World Validation of Molecular International Prognostic Scoring System for Myelodysplastic SyndromesElisabetta Sauta, Marie Robin, Matteo Bersanelli, et al.
Blood Cancer Journal|July 15, 2025
Age-dependent phenotypic and molecular evolution of pediatric MDS arising from GATA2 deficiencyLili Kotmayer, Emilia J Kozyra, Guolian Kang, et al.
The New England Journal of Medicine|January 9, 2020
Luspatercept in Patients with Lower-Risk Myelodysplastic SyndromesPierre Fenaux, Uwe Platzbecker, Ghulam J Mufti, et al.
Leukemia|April 30, 2026
How should myelodysplastic neoplasms with isolated deletion 5q and TP53 multihit alterations be classified?Maria Julia Montoro, Pamela Acha, Claudia Haferlach, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 27, 2026
Molecular-Based Ecosystem to Improve Personalized Medicine in Chronic Myelomonocytic LeukemiaLuca Lanino, Anthony M Hunter, Nico Gagelmann, et al.
Leukemia & Lymphoma|August 25, 2012
Rationale for the clinical application of flow cytometry in patients with myelodysplastic syndromes: position paper of an International Consortium and the European LeukemiaNet Working GroupArjan A van de Loosdrecht, Robin Ireland, Wolfgang Kern, et al.
Pageof 34